| 摘要 |
Patent No. 595193 Disclosed is the use of a modified non-complement protease, or a catalytically active portion thereof, for formulation of a medicament for inhibiting complement activation to effect treatment of an inflammatory disease or disorder, wherein: the non-complement protease, or catalytically active portion thereof, comprises modifications at an amino acid residue that is a determinant of specificity compared to an unmodified or scaffold protease; the scaffold protease is an MT-SP1 protease or a catalytically active portion thereof; the modified amino acid residue(s) increases one or both of specificity for a target substrate or activity towards a target substrate, wherein the target substrate is a complement protein; and the non-complement protease, or a catalytically active portion thereof, when contacted with any one or more target substrates of a complement pathway, results in cleavage of the target substrate protein such that complement activation in a pathway comprising the target substrate is inhibited, whereby inhibition of complement activation leads to a reduction of inflammatory symptoms associated with the disease or disorder, thereby treating the disease or disorder . |
